United States: HRSA Takes Its First Steps On 340B Rules

The 340B Drug Discount Program has operated for more than 20 years with just a few governing regulations codified in 42 CFR Part 10.  Through the Affordable Care Act ("ACA"), Congress adopted several amendments to the 340B Program.  One of those amendments required the Department of Health and Human Services ("HHS") to impose a maximum $5000 civil monetary penalty on participating manufacturers for each instance in which the manufacturer knowingly and intentionally charged a participating 340B entity a purchase price for a 340B drug that exceeds the statutory ceiling price.  Congress specifically authorized the Health Resources and Services Administration ("HRSA") to promulgate regulations implementing this requirement within 180 days of the ACA enactment, i.e. by September 2010.

And in fact, in September 2010 HRSA published an Advance Notice of Rulemaking on this requirement, seeking stakeholder input on the requirement.

Finally, on June 17, 2015, HRSA issued proposed rules to implement that requirement.  What took so long?  HRSA's commentary to the proposed rules, combined with the recent history of the 340B Program, provide the answers.  These proposed rules may be the first steps, but not the last, in what may be major changes to the 340B Program.

340B Program Recent History

We have written about the criticisms regarding 340B Program operations, which surfaced in a critical 2011 GAO Report and intensified over the next several years.   In response, HRSA went to work on an omnibus rule that would clarify multiple aspects of 340B Program operations, promising publication of that rule by June 2014.

But before the omnibus rule was made public, a DC Circuit Judge struck down a limited rule that HRSA had issued to implement another ACA requirement, an exception to 340B pricing for orphan drugs.  Unlike the monetary penalty provision in the ACA, the orphan drug provision contained no authority for HRSA rulemaking, and the Court found that HRSA lacked authority to issue the orphan drug rule.  As a result of that case, HRSA pulled back its omnibus rule and many commentators, including me, predicted that HRSA would instead issue limited rules in areas where it had specific rule making authority, such as the penalty authority.

Proposed Rules

The newly proposed rules, which would be codified within 42 CFR Part 10, address two ACA provisions:  (i) the requirement that HRSA adopt regulations penalizing manufacturers for overcharging ceiling prices, and (ii) a separate requirement that HRSA "develop and publish through an appropriate policy or regulatory issuance, precisely defined standards and methodology for the calculation of [340B] ceiling prices."  Because the statutory language does not specifically authorize rulemaking on calculation of ceiling prices, this portion of the rule may be the subject of comments or future legal challenges.  Comments to the proposed rules must be submitted by Monday, August 17, 2015.

Proposed Rule on Penalties

The proposed rules would allow HRSA to assess penalties of up to $5000 for each instance in which a manufacturer "knowingly and intentionally" charges a covered entity more than the ceiling price for a 340B drug.  The commentary clarifies that HHS-OIG will have the authority to bring the penalty actions pursuant to a delegation of authority and utilizing OIG's CMPL procedures codified in 42 CFR part 1003, but does not provide any specifics, just which provisions of part 1003 are applicable in the context of 340B.

Section 10.11(b)(1) of the proposed rule would define each "instance" of overcharging as each order for an NDC, regardless of the number of units of each NDC in that order,  and regardless of whether the order is placed directly with a manufacturer or through a wholesaler, authorized distributor, or agent.  Section 10.11(b)(5) then states that a manufacturer's failure to provide the ceiling price is not an actionable instance of overcharging if "a covered entity did not initially identify the purchase to the manufacturer as 340B-eligible at the time of purchase" (emphasis added).  This leaves open the question:  what is a 340B covered entity's obligation to specify that the purchase is for 340B when purchasing from a wholesaler, authorized distributor or agent, and what impact does its failure to do so have on the manufacturer's liability?

Additionally, neither the commentary nor the rule provides insight into this question:  will the government define "knowingly and intentionally" as requiring specific intent, or will some other standard be used?

Proposed Rule on Calculating Ceiling Price

Section 10.10(a) of the proposed rule incorporates the original statutory requirement that 340B ceiling price be calculated by subtracting the Medicaid Drug Rebate Unit Rebate Amount ("URA") from the reported Average Manufacturer Price ("AMP") for the smallest unit of measure calculated using six decimal places.  To ensure utility of the pricing, HRSA multiplies that amount by the drug's package size and case package size.  HRSA will publish the 340B ceiling price rounded to two decimal places.

Section 10.10(b) of the proposed rule also codifies HRSA's 2011 policy  regarding so-called "penny pricing."  For certain drugs, the Medicaid Drug Rebate Program authorizes CMS to index URA to the rate of inflation and increase the URA if the AMP for the drug increased faster than inflation.  When this increase is factored into the 340B ceiling price calculation for certain drugs, it is possible that the 340B price could come out to $0.00 per unit of measure.  For those drugs, the rule instead authorizes a 340B ceiling price of $0.01 per unit of measure.

Section 10.10(c) of the proposed rule codifies HRSA's guidelines, first published in 1995, on calculating ceiling price for new drugs which lack prior sales data.

What's Next?

HRSA has indicated it is already working on proposed rules in another area in which it has specified rulemaking authority:  implementation of a dispute resolution process.  HRSA has also indicated that before the end of 2015, it intends to publish protocols for audits of pharmaceutical manufacturers and to operationalize a system that will allow 340B covered entities to access information verifying 340B ceiling prices.  And purportedly, in lieu of its omnibus rule, HRSA is working on "omnibus guidance" to address multiple areas, including several recommendations first made in the 2011 report: (i) clarifying hospital eligibility standards for 340B, and (ii) the definition of a 340B "patient."

In the meantime, it is possible that Congress won't wait for HRSA to act.  On March 25, 2015, the House Energy & Commerce Committee held its first hearing on the 340B Program in years.  As we previously noted, the written testimony from that hearing focused on the lack of clear guidelines and accountability in 340B.  In the wake of that hearing, Committee staff circulated a draft of provisions to be included in the 21st Century Cures bill specific to 340B.  Clearly intended as a compromise measure, the legislation would have defined a 340B "patient," eliminated 340B status for drugs self-administered by patients at home, imposed greater accountability for hospitals and contract pharmacies, imposed a user fee, and required annual reporting by hospitals on 340B drug usage and resulting revenue, including reporting on how that revenue is used.  The legislation would also have allowed Medicaid Programs direct access to 340B price information to better enable the government to audit Medicaid billings for 340B drugs.   While stakeholder pushback caused the 340B provisions to be removed from the 21st Century Cures bill, Congressional interest in 340B operations is not waning.

So, whether the next move to alter 340B Program operations comes from Congress or from HRSA remains to be seen.  But one thing seems sure: there will be a next move.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Ellyn Sternfield
Bridgette A. Wiley
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions